<SEC-DOCUMENT>0001129928-13-000028.txt : 20130509
<SEC-HEADER>0001129928-13-000028.hdr.sgml : 20130509
<ACCEPTANCE-DATETIME>20130509082738
ACCESSION NUMBER:		0001129928-13-000028
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130331
FILED AS OF DATE:		20130509
DATE AS OF CHANGE:		20130509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		13826602

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>firstqurter2013mda.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>6-K - March 31, 2013 MD&A</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s96d5f1996c2246d3a258641903f1ea8c"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;  </font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Form 6-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Foreign Private Issuer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the month of&#160;May 2013</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number 000-31062</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Translation of registrant&#8217;s name into English)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite&#160;210, 1167 Kensington Crescent NW</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Calgary, Alberta, Canada T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Address of principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="40%"></td><td width="20%"></td><td width="40%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;20-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;40-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="40%"></td><td width="20%"></td><td width="40%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s34514EC99986B60AC4A986204E50A50D"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="17%"></td><td width="1%"></td><td width="82%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Inc. March 31, 2013 Management Discussion &amp; Analysis</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="52%"></td><td width="3%"></td><td width="4%"></td><td width="3%"></td><td width="38%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;&#160;May 9, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>2
<FILENAME>ex151firstquarter2013mda.htm
<DESCRIPTION>FIRST QUARTER 2013 MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>EX. 15.1 - Q1 2013 MD&A</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s7DE26EB135FE688B16383CC8A35AB3CA"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;"><img src="finalonclogo.jpg" style="height:160px;width:682px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><br><div></div><hr style="page-break-after:always"><a name="s74E6CA8E58D4C6327DC43CC8A37AD9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">May&#160;8, 2013</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This discussion and analysis should be read in conjunction with the unaudited consolidated interim financial statements of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Oncolytics Biotech Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;as at and for the three months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) contained in our annual report for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.  The financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;).  </font></div><a name="sC7931816382DAA72A80E3CC8A3B53F99"></a><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including our belief as to the potential of REOLYSIN&#174;, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in 2013 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for, and availability of, funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research, development and manufacturing of pharmaceuticals, changes in technology, general changes to the economic environment and uncertainties related to the regulatory process. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of REOLYSIN and future expense levels being within our current expectations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are based on assumptions, projections, estimates or expectations of management at the time to be uncertain and forward-looking. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div><a name="sD3C27F17BECEED700E203CC8A3CF1EFF"></a><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN, our potential cancer therapeutic.  We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.  We do not expect to generate significant revenues until, if and when, our cancer product becomes commercially viable.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance REOLYSIN through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><a name="s83C7B34EA5E30351A18F3CC8A4000718"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial program is made up of randomized and non-randomized clinical trials that are sponsored by Oncolytics and by third parties. We began 2013 with a clinical program consisting of 16 clinical trials which includes seven randomized clinical trials.  Of these 16 clinical trials, we fund four clinical trials and third parties sponsor the other 12.  During the first quarter of </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013, we completed enrollment in our U.S. phase II non-small cell lung cancer clinical trial and announced clinical trial results from our phase II squamous cell lung cancer trial.  We exited the first quarter of 2013 with 16 clinical trials.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Clinical Trial - Randomized Phase III Head and Neck Pivotal Trial</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2013, we continued to re-treat patients that had been previously enrolled in stage one of our global randomized Phase III head and neck pivotal trial but had not yet progressed.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Clinical Trial - Third Party Clinical Trials</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We began 2013 with 12 third party sponsored clinical trials ("Third Party Trials"). Third Party Trials have allowed us to expand our clinical program to include additional cancer indications (pancreatic, ovarian, colorectal, prostate, breast, squamous cell carcinoma, lung cancer and multiple myeloma) while allowing us to remain focused on our global randomized Phase III head and neck trial, our non-small cell lung cancer trial and complete our other clinical trials.  Our Third Party Trials require that we supply enough REOLYSIN for the enrollment requirements of each trial, sufficient intellectual capital to support the principal investigators and in some cases cost sharing of patient enrollment activities.   The institutions involved provide the rest of the required activities to operate the clinical trial.  These activities include patient screening and enrollment, treatment, monitoring and overall clinical trial management and reporting.  The result is a larger clinical program investigating more cancer indications at a significantly reduced financial  cost to Oncolytics.  Our Third Party Trials are sponsored by the U.S. National Cancer Institute (&#8220;NCI&#8221;), the National Cancer Institute of Canada Clinical Trials Group ("NCIC"), the Cancer Therapy &amp; Research Center at The University of Texas Health Center in San Antonio (&#8220;CTRC&#8221;), and the University of Leeds (&#8220;Leeds&#8221;).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Clinical Trial - Results</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Phase II Squamous Cell Carcinoma Clinical Trial </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2013, we met the primary overall statistical endpoint in our U.S. Phase II single arm clinical trial in patients with squamous cell carcinoma of the lung ("SCCLC") using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy na&#239;ve for their metastatic or recurrent cancer.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The study is a two-stage design with a primary overall endpoint of objective tumor response rate.  During the first stage, we saw a sufficient number of responses to proceed with enrollment in the second stage.  A total of up to 36 patients were to be studied in the second stage with the primary endpoint being met if nine or more patients in both stages combined had a partial response ("PR") or better, effectively yielding a true response rate of 35% or more. This endpoint was met after 21 evaluable patients were treated on study, nine of which exhibited PRs, while a further nine showed stable disease ("SD") and three, progressive disease ("PD"), for a response rate of 42.8% and a disease control rate (complete response (CR) + PR + SD) of 85.7%. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in the first quarter of 2013, we also announced clinical results examining percent overall tumour shrinkage data from this trial.  The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles. Of 20 evaluable patients examined, 19 (95%) exhibited overall tumour shrinkage (mean for the 20 patients: 33.7% shrinkage). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Phase I Metastatic Colorectal Cancer Clinical Study</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2013, we presented a poster covering positive preliminary results from a Phase I study examining the intravenous administration of REOLYSIN in combination with FOLFIRI in patients with metastatic colorectal cancer (REO 022) at the ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, which took place from January 2013.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The poster presentation, titled: "A Multicenter Phase I Study of Intravenous Administration of REOLYSIN in combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients (pts) with Oxaliplatin-Refractory/Intolerant KRAS-Mutant Metastatic Colorectal Cancer (mCRC)," was authored by Ocean et al. Twenty-one patients were enrolled in the study, including nine that were FOLFIRI-na&#239;ve. Of the 18 patients evaluable for response there was one partial response and nine had stable disease. The combined overall progression free survival (PFS) of FOLFIRI-na&#239;ve and FOLFIRI-failed patients was 7.4 months.  The authors concluded that the combination of REOLYSIN and FOLFIRI was safe and well tolerated and resulted in disease control in the majority of evaluable patients, including patients that had previously progressed on Irinotecan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial was a 21-patient, single arm dose escalation study designed to determine a maximum tolerated dose and dose-limiting toxicities for the combination of REOLYSIN and FOLFIRI.  Eligible patients included those with histologically confirmed cancer of the colon or rectum with Kras mutation and measurable disease. They must have progressed on or within 190 after the last dose of an oxaliplatin regimen in the metastatic setting, or be intolerant to oxaliplatin.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Clinical Trial - Completed Enrollment </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Phase II Non-Small Cell Lung Cancer Clinical Study</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2013, we completed patient enrollment in our Phase II  clinical trial evaluating intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer ("NSCLC") with Kras or EGFR-activated tumours.  This trial is a single arm, single-stage, open-label, Phase II study of REOLYSIN given intravenously with paclitaxel and carboplatin every three weeks. Patients received four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN, following which REOLYSIN could be continued as a monotherapy.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eligible patients included those with metastatic or recurrent NSCLC with Kras or EGFR-activated tumours, who had not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in Kras or EGFR, or EGFR gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s269F9583FA56582D026C3CC8A4213A03"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2013, we continued our validation activities designed to demonstrate that our manufacturing process for the commercial production of REOLYSIN is robust and reproducible as part of a process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the US Food and Drug Administration, for product approval. </font></div><a name="s5DCA9D62C1D4B5CE02D93CC8A4537973"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">,  we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">360</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">49</font><font style="font-family:inherit;font-size:10pt;">&#32;U.S. and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions.  We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><a name="sE222049E4D3714FCCCBB3CC8A4A632F2"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Underwritten Public Offering </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2013, we closed a U.S. underwritten public offering whereby we issued 8,000,000 common shares at an issue price of U.S.$4.00 per common share for gross proceeds of U.S.$32,000,000. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, we received cash proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;with respect to the exercise of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">48,533</font><font style="font-family:inherit;font-size:10pt;">&#32;stock options.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sFDCD9CF7FB5342FCBB793CC8A4C8F431"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated at the beginning of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;that our cash requirements to fund our operations would be approximately $20.0 million.  Our cash usage for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,410,222</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;from  operating activities and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,138</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment.  Our net loss for the period was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6,606,836</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sA9FFFA4F77A3ADB44A083CC8A4FA18A5"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We exited the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash and short-term investments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$43,521,301</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sAC7937C68D575FD52D593CC8A51B6459"></a><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development For 2013</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned development activity for REOLYSIN in 2013 is made up of clinical, manufacturing, and intellectual property programs.  Our 2013 clinical program includes the anticipated release of clinical data from our randomized U.S. Phase III head and neck cancer trial, our randomized U.S. Phase II pancreatic cancer trial, and our randomized U.S. Phase II ovarian cancer trial.  As well, we expect to release additional clinical data from our lung cancer trials.  These results will assist in the determination of our regulatory path and the next steps for our clinical program.  As well, we expect enrollment to continue in our Third Party Trials throughout 2013.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2013 manufacturing program includes several 100-litre cGMP production runs along with the related fill, labeling, packaging and shipping of REOLYSIN to our various clinical sites.  We also plan to continue progressing through our process validation master plan and related conformity testing in 2013.  Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still estimate the cash requirements to fund our operations for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;will be approximately $20,000,000, but will depend on our ultimate clinical program.  (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s6C58BC0369B3C238952D3CC8A54DA169"></a><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the three month period ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;was</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6,606,836</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,458,528</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;compared to for the three month period  ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.     </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="384px"></td><td width="75px"></td><td width="4px"></td><td width="75px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,090,446</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,229,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">552,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,859,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">216,370</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,585</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">824,999</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,245,378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">360,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,117,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,490,544</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="376px"></td><td width="75px"></td><td width="4px"></td><td width="68px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct patient expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,090,446</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,846,568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase III start up expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,090,446</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,229,666</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial expenses for the first quarter of 2013 were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$3,090,446</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$4,229,666</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the first quarter of 2012.  During the first quarter of 2013, our clinical trial program activities relating to our global randomized Phase III head and neck trial declined as a result of the pause in enrollment.  In the first quarter of 2013, we were incurring direct patient costs associated with the re-treatment of patients enrolled in our global randomized Phase III head and neck clinical trial.  In addition, we incurred direct patient costs associated with our 12 Third Party Trials which include the four randomized clinical studies that are part of the clinical research agreement with the NCIC.    In the first quarter of 2012, we incurred direct patient costs associated with the completion of stage 1 enrollment of our global randomized Phase III head and neck trial along with the other clinical trials that we were sponsoring.  By the end of the first quarter of 2012, we were actively enrolling patients at over 80 clinical sites in over 13 jurisdictions.  </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our clinical trial expenses to decrease in 2013 compared to 2012.  Our clinical program includes 12 Third Party Trials and only four Company sponsored trials.  We expect to incur support costs associated with our Third Party Trials, but these costs are expected to be less than the typical costs associated with directly funding similar clinical trials.   In addition,  we expect to complete enrollment in the four clinical trials that we are currently sponsoring.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="71%"></td><td width="14%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,375</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,241,068</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552,965</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,859,801</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for the first quarter of 2013 were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$552,965</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,859,801</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2012.  During the first quarter of 2013, our product manufacturing costs mainly related to shipping and storage activities.  During the first quarter of 2012, we completed our first 100-litre cGMP production run of 2012.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for the first quarter of 2013 were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$329,590</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$618,733</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2012.  During the first quarters of 2013 and 2012, our process development activities focused on our validation master plan.  These activities included optimization, validation and stability studies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our M&amp;P expenses for 2013 to remain consistent with 2012.  We expect to complete several 100-litre cGMP production runs including fill and finish activities in 2013.  We also expect to continue to perform conformity testing related to our process validation master plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="74%"></td><td width="11%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,370</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,585</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$216,370</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$160,585</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.  The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base.  At the end of the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">360</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">49</font><font style="font-family:inherit;font-size:10pt;">&#32;U.S. and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.  We still expect that our intellectual property expenses will remain consistent in 2013 compared to 2012.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="76%"></td><td width="11%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,618</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,565</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;were  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$68,618</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$30,565</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.  Our research collaboration activities in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;focused on the interaction of the immune system and the reovirus and the use of the reovirus as a co-therapy with existing chemotherapeutics and radiation.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our research collaborations in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;will remain consistent with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.  We expect to complete our ongoing collaborative program carried over from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;and will continue to be selective in the types of new collaborations we enter into in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="70%"></td><td width="14%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D consulting fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,848</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,892</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">736,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,748</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">824,999</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,245,378</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Other Research and Development expenses for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$824,999</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,245,378</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.  During the first quarter of 2013, our Other Research and Development activities declined as a result of the pause in enrollment in our global randomized Phase III head and neck trial.  As well, with the shift to Third Party Trials, our current clinical program requires less support.  During the first quarter of 2012, we were supporting  our global randomized Phase III head and neck trial that was actively enrolling in over 80 clinical sites in 14 countries.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our Other R&amp;D expenses in 2013 will remain consistent compared to 2012. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="70%"></td><td width="14%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2013<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2012<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">890,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,944</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,564,751</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,088,051</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings.   In the first quarter of 2013, our investor relations activities, in anticipation of our financing, along with our financial advisory service activities increased compared to the first quarter of 2012.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent, travel, and other office related costs.  During the first quarter of 2013, we incurred office expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$531,782</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$365,650</font><font style="font-family:inherit;font-size:10pt;">&#32;during the first quarter of 2012. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, our office expenses increased compared to 2012 in an effort to support our increased investor relations activity along with an increase in salaries associated with the addition of our general council.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2013, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$117,944</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,415</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2012.  We incurred stock based compensation associated with the grant of stock options in the first quarter of 2013 as a result of hiring our general council.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our operating expenses in 2013 to remain consistent with 2012.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, we are committed to payments totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,107,000</font><font style="font-family:inherit;font-size:10pt;">&#32;during the remainder of 2013 for activities related to clinical trial activity, manufacturing and collaborations.  All of these committed payments are considered to be part of our normal course of business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sE59D5D0C34E1E067D6DB3CC8A56EFDFA"></a><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:614px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td width="189px"></td><td width="9px"></td><td width="59px"></td><td width="4px"></td><td width="9px"></td><td width="36px"></td><td width="4px"></td><td width="9px"></td><td width="38px"></td><td width="4px"></td><td width="9px"></td><td width="36px"></td><td width="4px"></td><td width="9px"></td><td width="36px"></td><td width="4px"></td><td width="9px"></td><td width="38px"></td><td width="4px"></td><td width="9px"></td><td width="36px"></td><td width="4px"></td><td width="9px"></td><td width="38px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td><td colspan="9" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2011</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,179</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,459</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,677</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,232</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,272</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,561</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,690</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Included in total cash are cash and cash equivalents plus short-term investments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Included in net loss and loss per common share between March 2013 and April 2011 are quarterly stock based compensation expenses</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(recovery) of  $120,856, $780,240, ($121,685), $58,343, $13,853, $1,580,978, $181,183, and $40,469,  respectively.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">We issued </font><font style="font-family:inherit;font-size:8pt;color:#000000;text-decoration:none;">8,048,533</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares  for net cash proceeds of  </font><font style="font-family:inherit;font-size:8pt;color:#000000;text-decoration:none;">$30.3 million</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2013 (2012 - 5,458,950 common shares for net cash proceeds of $20.8 million; 2011 - 3,293,033 common shares for net cash proceeds of $14.8 million).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><a name="s5D8806ABBF95EC4E4F443CC8A5A90022"></a><div style="line-height:120%;padding-bottom:16px;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><a name="s1729BD6D10115C94E7D33CC8A5C3E940"></a><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2013 Financing Activities</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Underwritten Public Offering </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2013, we closed a U.S. underwritten public offering whereby we issued 8,000,000 common shares at an issue price of U.S.$4.00 per common share for gross proceeds of U.S.$32,000,000. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, we received cash proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;with respect to the exercise of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">48,533</font><font style="font-family:inherit;font-size:10pt;">&#32;stock options.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2012 Financing Activities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Public Offering - Bought Deal</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 8, 2012, we closed a bought deal financing whereby we issued 5,065,750 common shares at an issue price of $4.20 per common share for gross proceeds of $21,276,150.  In connected with this bought deal financing, we issued 303,945 compensation options to the underwriters with an exercise price of $4.20 per option expiring on February 8, 2014.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout the first quarter of 2012, we received cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;with respect to the exercise of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">147,166</font><font style="font-family:inherit;font-size:10pt;">&#32;stock options.</font></div><a name="s2AF3763830869418EFE13CC8A0D0FDBF"></a><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents, short-term investments and working capital positions as follows: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="72%"></td><td width="13%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2013</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2012</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41,519,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,323,541</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,001,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">38,647,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,786,780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board .&#160;&#160;The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities.&#160;&#160;The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 3, 2012, we renewed our short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;). Under our Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf expires on August 3, 2014.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2013.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s2D92D52FCE26A025E34A3CC8A6173F10"></a><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our Investment Policy, we are permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with terms less than two years.  Our portfolio consists of guaranteed investment certificates.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;invested under this policy, currently earning interest at an effective rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.50%</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><a name="sBB32553A726427923DA33CC8A6491CA3"></a><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable.  As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.  These financial instruments expose us to the following risks:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents and short-term investments in the event of non-performance by </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">counterparties, but we do not anticipate such non-performance.&#160;&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and short-term investments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&#160;&#160;Currently, 100% of our short-term investments are in guaranteed investment certificates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;&#160;We are exposed to currency risk from the purchase of goods and services primarily in the U.S. and the U.K. and to the extent cash is held in foreign currencies.&#160;&#160;The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$237,901</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$26,432</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$87,371</font><font style="font-family:inherit;font-size:10pt;">&#32;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk through the purchase of foreign currencies in sufficient amounts to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:420px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="197px"></td><td width="75px"></td><td width="4px"></td><td width="70px"></td><td width="4px"></td><td width="64px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">U.S. dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,355,642</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,527</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,715</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,208,773</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,146,869</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,382</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,613</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 8 of our interim financial statements.&#160;&#160;Accounts payable are all due within the current operating period.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sAE690B15CE9A9E44CAC43CC8A669720D"></a><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">84,758,818</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">May&#160;8, 2013</font><font style="font-family:inherit;font-size:10pt;">.  If all of our warrants (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">303,945</font><font style="font-family:inherit;font-size:10pt;">) and options (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6,076,844</font><font style="font-family:inherit;font-size:10pt;">) were exercised we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">91,139,607</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;Annual Information Form on Form 20-F is available on www.sedar.com.</font></div><a name="s4394717E8193D2146DFC3CC8A69C750A"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting during the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;that materially affected or are reasonably likely to materially affect, internal controls over financial reporting.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;">9</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>finalonclogo.jpg
<TEXT>
begin 644 finalonclogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_[2Q64&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/J`````!VP/#]X;6P@=F5R<VEO
M;CTB,2XP(B!E;F-O9&EN9STB551&+3@B/SX*/"%$3T-465!%('!L:7-T(%!5
M0DQ)0R`B+2\O07!P;&4@0V]M<'5T97(O+T141"!03$E35"`Q+C`O+T5.(B`B
M:'1T<#HO+W=W=RYA<'!L92YC;VTO1%1$<R]0<F]P97)T>4QI<W0M,2XP+F1T
M9"(^"CQP;&ES="!V97)S:6]N/2(Q+C`B/@H\9&EC=#X*"3QK97D^8V]M+F%P
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M970N;6]D1&%T93PO:V5Y/@H)"0D)/&1A=&4^,C`P."TP-2TR,E0R,3HR.#HU
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M<'!L92YP<FEN="YT:6-K970N;6]D1&%T93PO:V5Y/@H)"0D)/&1A=&4^,C`P
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M8VME="YM;V1$871E/"]K97D^"@D)"0D\9&%T93XR,#`X+3`U+3(R5#(Q.C(X
M.C4P6CPO9&%T93X*"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT+G1I8VME="YS
M=&%T949L86<\+VME>3X*"0D)"3QI;G1E9V5R/C`\+VEN=&5G97(^"@D)"3PO
M9&EC=#X*"0D\+V%R<F%Y/@H)/"]D:6-T/@H)/&ME>3YC;VTN87!P;&4N<')I
M;G0N4&%G949O<FUA="Y0359E<G1I8V%L4V-A;&EN9SPO:V5Y/@H)/&1I8W0^
M"@D)/&ME>3YC;VTN87!P;&4N<')I;G0N=&EC:V5T+F-R96%T;W(\+VME>3X*
M"0D\<W1R:6YG/F-O;2YA<'!L92YP<FEN=&EN9VUA;F%G97(\+W-T<FEN9SX*
M"0D\:V5Y/F-O;2YA<'!L92YP<FEN="YT:6-K970N:71E;4%R<F%Y/"]K97D^
M"@D)/&%R<F%Y/@H)"0D\9&EC=#X*"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT
M+E!A9V5&;W)M870N4$U697)T:6-A;%-C86QI;F<\+VME>3X*"0D)"3QR96%L
M/C$\+W)E86P^"@D)"0D\:V5Y/F-O;2YA<'!L92YP<FEN="YT:6-K970N8VQI
M96YT/"]K97D^"@D)"0D\<W1R:6YG/F-O;2YA<'!L92YP<FEN=&EN9VUA;F%G
M97(\+W-T<FEN9SX*"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT+G1I8VME="YM
M;V1$871E/"]K97D^"@D)"0D\9&%T93XR,#`X+3`U+3(R5#(Q.C(X.C4P6CPO
M9&%T93X*"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT+G1I8VME="YS=&%T949L
M86<\+VME>3X*"0D)"3QI;G1E9V5R/C`\+VEN=&5G97(^"@D)"3PO9&EC=#X*
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M96%L/@H)"0D)"0D\<F5A;#XP+C`\+W)E86P^"@D)"0D)"3QR96%L/C<S-#PO
M<F5A;#X*"0D)"0D)/')E86P^-3<V/"]R96%L/@H)"0D)"3PO87)R87D^"@D)
M"0D)/&ME>3YC;VTN87!P;&4N<')I;G0N=&EC:V5T+F-L:65N=#PO:V5Y/@H)
M"0D)"3QS=')I;F<^8V]M+F%P<&QE+G!R:6YT:6YG;6%N86=E<CPO<W1R:6YG
M/@H)"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT+G1I8VME="YM;V1$871E/"]K
M97D^"@D)"0D)/&1A=&4^,C`P."TP-2TR,E0R,3HR.#HU,%H\+V1A=&4^"@D)
M"0D)/&ME>3YC;VTN87!P;&4N<')I;G0N=&EC:V5T+G-T871E1FQA9SPO:V5Y
M/@H)"0D)"3QI;G1E9V5R/C`\+VEN=&5G97(^"@D)"0D\+V1I8W0^"@D)"3PO
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M+C`\+W)E86P^"@D)"0D)"3QR96%L/C<S-#PO<F5A;#X*"0D)"0D)/')E86P^
M-3<V/"]R96%L/@H)"0D)"3PO87)R87D^"@D)"0D)/&ME>3YC;VTN87!P;&4N
M<')I;G0N=&EC:V5T+F-L:65N=#PO:V5Y/@H)"0D)"3QS=')I;F<^8V]M+F%P
M<&QE+G!R:6YT:6YG;6%N86=E<CPO<W1R:6YG/@H)"0D)"3QK97D^8V]M+F%P
M<&QE+G!R:6YT+G1I8VME="YM;V1$871E/"]K97D^"@D)"0D)/&1A=&4^,C`P
M."TP-2TR,E0R,3HR.#HU,%H\+V1A=&4^"@D)"0D)/&ME>3YC;VTN87!P;&4N
M<')I;G0N=&EC:V5T+G-T871E1FQA9SPO:V5Y/@H)"0D)"3QI;G1E9V5R/C`\
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M"0D)/&1A=&4^,C`P,RTP-RTP,50Q-SHT.3HS-EH\+V1A=&4^"@D)"0D)/&ME
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M="Y!4$E697)S:6]N/"]K97D^"@D\<W1R:6YG/C`P+C(P/"]S=')I;F<^"@D\
M:V5Y/F-O;2YA<'!L92YP<FEN="YT:6-K970N<')I=F%T94QO8VL\+VME>3X*
M"3QF86QS92\^"@D\:V5Y/F-O;2YA<'!L92YP<FEN="YT:6-K970N='EP93PO
M:V5Y/@H)/'-T<FEN9SYC;VTN87!P;&4N<')I;G0N4&%G949O<FUA=%1I8VME
M=#PO<W1R:6YG/@H\+V1I8W0^"CPO<&QI<W0^"CA"24T#Z0``````>``#````
M2`!(``````+>`D#_[O_N`P8"4@-G!2@#_``"````2`!(``````+8`B@``0``
M`&0````!``,#`P````%__P`!``$```````````````!H"``9`9```````"``
M`````````````````````````````````#A"24T#[0``````$`$L`````0`!
M`2P````!``$X0DE-!"8```````X`````````````/X```#A"24T$#0``````
M!````!XX0DE-!!D```````0````>.$))30/S```````)```````````!`#A"
M24T$"@```````0``.$))32<0```````*``$``````````3A"24T#]0``````
M2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:
M````!@```````0`U`````0`M````!@```````3A"24T#^```````<```____
M_________________________P/H`````/__________________________
M__\#Z`````#_____________________________`^@`````____________
M_________________P/H```X0DE-!`````````(``#A"24T$`@```````@``
M.$))300(```````0`````0```D````)``````#A"24T$'@``````!``````X
M0DE-!!H``````T4````&``````````````#A```#P`````@`3P!.`$,`(`!,
M`&\`9P!O`````0`````````````````````````!``````````````/`````
MX0`````````````````````!`````````````````````````!`````!````
M````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````!```
M``!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````
MX0````!29VAT;&]N9P```\`````&<VQI8V5S5FQ,<P````%/8FIC`````0``
M````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO
M;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'
M96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````
M!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`````
M`````$QE9G1L;VYG``````````!"=&]M;&]N9P```.$`````4F=H=&QO;F<`
M``/``````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````37-G
M951%6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X=$ES
M2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE
M;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG
M;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO
M<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P
M3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O
M;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H
M```````,`````3_P````````.$))3004```````$`````CA"24T$#``````(
M2`````$```"@````)@```>```$=````(+``8``'_V/_@`!!*1DE&``$"`0!(
M`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(
M#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,
M#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`)@"@`P$B
M``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*
M"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4#
M##,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q
M8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$`
M`A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R
M@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]56/U+ZQ,Q\S]F]/
MQW]3ZF`'/QZ2&MK:?HNS,E_Z+&W?F?X7_@T7ZQ]2NZ;TFV_&:'Y=A;1B,/>Z
MYPIH_P`U[_44^B='HZ1@MQJR;;GDV962[5]USO==?:[Z3G/<FDDFAIW*FCO^
MO3O>*NEU`Z^DY][G#^2ZUK&L_P#`TJ?K+=C9->'U_#/3+;B&49(>+<6QQXK;
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M,?IQ;B8[?MG5K],7`J,O<?W[?]!CM^G9=;^8B2!NAK],(L^MO6GL^C73AU/\
M[(NM_P"C7;6LJC$ZB>M]<ZATDQGXN4P''L);5DTNIJ<[%?/MJMW^_&RO\%9_
M.?H;%T'U?Z59TS!<W)L%V=E6.R<ZYH@.NL^GL_X*MNVJK_@V)JNLOLS_`+&<
M5[1ZUE'J<QZ;/5;<]FWVTW?099]!,K07IJ3_`(R6A]4;V9.3UK)K994V[,#O
M3N:66-/HT-LKLK=]%]=K7UJETW]EC(S!];!5^U#?9L=G@>CZ$_JXZ:[)_5OL
M^SZ3:?TWJ?TGWKJ<G)-%F,P5NL^TV^D7-X8/3MN]1_\`(_0^G_UQ1S\MV)C^
MLVIUQ+V,AO#0]P9ZMKO=LHJW>I=9M_1UH\.F_P`OAHIS.I![OJKD-^JX:QWI
M.&(,<!GYWZ7[/]';9_.^E_PBSO\`L%/2X+*&7;/H;8Z@+(_=_P"4?MWJ?]>]
M1=%@YSLM][#46"AX:+6G=58"UMFZBV&>ILW>G;[/YU-]KR?VE]C]`>EZ?J^O
MN,1.S9M]/;ZO\CU/H)$`T=/W=E//YC>J._Q<7-ZH'G/.&X6A^MG?T_4V_P"%
M]+9ZG_"+9Z9UGI-[,?$HS*;,@UM`J:\%Q+6[G^WZ7M:U'ZEU!V"V@BDW>O;Z
M1(,!@V67>I8Z'>W]#Z?]>Q6JG^I6Q^GN:':&1J/S7:(@4=#L`-5/,=<QLGHN
M57E]$M&,[K.0S$R:7,]2IMUTBOJE=4M]/(JV_I_\#E_X;](MC`Z%T["P'X/I
MC(KN)?E/R(L??8[6R[*<_P#G7O=_ZC1.G=1=FM#S6*-S=WHO<?69K&S(HV?H
M;/W_`-+8BY64['LQF-I?=]HM-1+(]@%=M_J/W>W9^A]/_KB0`U/0J>=Z=T7H
M]GUFZSCV8&.^BJO$-5;J6%C2]MWJ^DQS?3;OV_I-BM?6D?K?0(''4J^!Q^CO
M\%L8&4[,QA>ZI]!+[&>G9HX>F]],N_K^GO5A`1'#0ZZ_]TIYOZR;_P!JX!ZB
M'N^KX:_[2&!QK]>1Z'[0;5[OL?\`7_5O5_I"O=+/U8^U._8XQ/M!K][L0,^@
M"-'OH&WZ?YBO8^4;LC*I-;F#&>U@>[A^ZNN[>S^KZOI_V%3ZCUJS`NO9]CNO
MKIH;<+:P7`O>;FUX^UK7.]WH?SOO]+U:_6]-GO2T!XOV*>>S*>CLS\Z]N?TW
M)MLM<ZVCJ]8?:QP]CJ,:]UE=C,1NW]#5]FO_`.#70?5F\7]'I>W!_9K`7M9C
MZANT.,6TAS:K/1N_G*_4JJ5W.RCAXK\@5/O+(_1UB7>YP9N_XNO=ZEO_``2E
MBWF^LO/IF#'Z)_J-_P`_96D(U+?\%/\`_]'U59O7OV#]@=^WO0^QS_VHB-W_
M``7Y_J_\5^D7S.DA+8[?793[HRCZI.JWXV3U=F'VKJ'4?1C^3^B=[/[:VOJS
M_P`U/3L_YO\`H[Y_3Q/K_P#H1]H_6_\`MU?.*2CCN/E^G_<I^U^JDE\JI*5#
M]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224__9.$))300A``````!3`````0$````/`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`
M<``@`$,`4P````$`.$))300&```````'``@````!`0#_X0E@17AI9@``24DJ
M``@````'`!(!`P`!`````0"+>1H!!0`!````8@```!L!!0`!````:@```"@!
M`P`!`````@"]#S$!`@`=````<@```#(!`@`4````D````&F'!``!````I```
M`,X````L`0```0```"P!```!````061O8F4@4&AO=&]S:&]P($-3($UA8VEN
M=&]S:`"`,C`P.#HP-3HR,B`Q-3HR.3HS.``#``&@`P`!`````0#__P*@!``!
M````P`,```.@!``!````X0`````````&``,!`P`!````!@#F_QH!!0`!````
M'`$``!L!!0`!````)`$``"@!`P`!`````@"DI0$"!``!````+`$```("!``!
M````+`@```````!(`````0```$@````!````_]C_X``02D9)1@`!`@$`2`!(
M``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"8`H`,!(@`"
M$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^L3,?,_9O3\=_
M4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^786T8C#WNN<*
M:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I))H:=RIH[_KT[
MWBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2'BW%L<>*VY(#
M/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4G26']5[\FMF7
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MK?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=_OQLK_!6?SGZ
M&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:KK+[,_P"QG%>T
M>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R:V65-NS`[T[F
MEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/ZN.FNR?U;[/L^
MDVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]<4<_+=B8_K-J
M=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJY#?JN&L=Z3AB
M#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`E'[=ZG_7O471
M8.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8_0'I>GZOK[C$
M3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9W]/U-O\`A?2V
M>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@MH(I-WKV^D2#
M`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#53S'7,;)Z+E5Y
M?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.A=.PL!^#Z8R*
M[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'UF:QLR*-GZ&S]
M_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3T*GG>G=%Z/9]
M9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!QU*O@<?H[_!;
M&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^LF_\`:N`>HA[O
MJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[0:_>[$#/H`C1
M[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:LP+KV?8[KZZ:
M&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH[,_.O;G]-R;;
M+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7MP?V:P%[68^H;
MM#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+KW>I;_P`$I8MY
MOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/L<_]J(C=_P`%
M^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_HG>S^VMKZL_\`
M-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?JI)?*J2E0_52
M2^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_522^54
MDE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN=')21T(@6%E:
M(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````````````````
M``#VU@`!`````-,M2%`@(```````````````````````````````````````
M````````````````````````$6-P<G0```%0````,V1E<V,```&$````;'=T
M<'0```'P````%&)K<'0```($````%')865H```(8````%&=865H```(L````
M%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````B'9U960```-,
M````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,````)'1E8V@`
M``0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,```0\```(#'1E
M>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M$G-21T(@245#-C$Y-C8M,BXQ````````````````````````````````````
M``````````````````````````````!865H@````````\U$``0````$6S%A9
M6B``````````````````````6%E:(````````&^B```X]0```Y!865H@````
M````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S8P`````````6
M245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#(&AT='`Z+R]W
M=W<N:65C+F-H````````````````````````````````````````````````
M`````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%0R`V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````
M``````````````!D97-C`````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````````
M````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X`
M```!6%E:(```````3`E6`%````!7'^=M96%S``````````$`````````````
M```````````"CP````)S:6<@`````$-25"!C=7)V````````!``````%``H`
M#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\
M`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`
M\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\
M`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\"
M.`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6
M`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$
M+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G
M!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&
MXP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"
M")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*
M:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU
M#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.
MT@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/
M$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84
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MN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(
M.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^
M8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#
M1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*
M-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q
M4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=7
M1%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:
M7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UE
MDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(
M;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU
M*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!
M?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&
M#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.
MCS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"8
M3)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&V
MHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6K
MZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!
MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`
M[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNV
MS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC7
M7-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;
MXV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O
M0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW
M_`?\F/TI_;K^2_[<_VW____;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3
M#Q0=&A\>'1H<'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!
M"0D)#`L,&`T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,O_``!$(`.$#P`,!(@`"$0$#$0'_Q``?```!
M!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!```
M`7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9
M&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY
M>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*
MTM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!
M`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%
M(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ
M-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z***`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBLC7/$NE^'H=]_<!7(RD*<NWT']3Q2
M;25V!KU2U#5].TJ/S+^\AMU[;VP3]!U->2Z[\3=5U`M%IP%A;GHR\R$?7M^'
MYUQ4T\MQ*99Y7DD;JSL23^)KEGBDOA*43V#4/BKHUL2MG!<79'\6-BG\^?TK
MG;KXM:I)D6MA:PCU<LY_I7GRJ68*H))[`5L6?A/7[\`V^DW)4]&=-@/XMBL?
M;59;#LC5E^)7B>0_+>11?[D"?U!J+_A8OBK_`*"8_P#`>+_XFK$/PR\22KEH
M;>+V>8?TS4__``JOQ!_STLO^_I_PHM7\PT*L7Q*\3QD;KR*7_?@3^@%:=K\6
MM5C(^U6-K,/]C<A_F:SYOAEXDB4E8;>7V289_7%9%YX1\06`+3Z3<A1U9$W@
M?BN:7-6CW#0])T_XK:1<$+>6UQ:D_P`0&]?TY_2NNT[6M-U:/?87L,X[A&^8
M?4=17S>RLC%64J1U!&*=%+)!(LD4C1NO(93@C\:N.*DOBU#E1].T5XKH?Q+U
M?32L5]B_MQQ\YQ(![-W_`!S7J.A>*=*\0Q9LK@>:!EH'X=?P[CW%=5.M&>Q+
M5C9HHHK404444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4A(`))P!0S*B%F8*H&2
M2<`"O'O&_CV35'DTW2I"EB"5DE'!F]O9?YUG4J*"NQI7-OQ;\24M&DL=#99)
MA\KW755_W?4^_3ZUY7<7,]W<//<2O+*YRSN<DU&!DX')KT/PI\-9;U4O=;W0
MP'E;8<.X_P!K^Z/U^E<#<ZTB]$<9I&A:EKEQY.GVKRD?>;HJ_4]!7H^B_"BV
MB"RZQ=-,_P#SQ@^51]6ZG\,5Z#9V5MI]LEM:01P0I]U$&!4]=4,-&/Q:DN1G
MZ?H>EZ4@6QL8(<?Q*@W?GUK0HHKH22V)"BBBF`4444`4-0T73-54K?6,$^?X
MF0;OSZUP^L_"BUF#2Z/=-`_:&8[E/T/4?K7H]%1*G&6Z'<^<=7T'4]"G\K4+
M5XLGY7ZJWT/0U1@GEMIDF@E>*5#E70X(/UKZ5NK2WOK9[>Z@CFA<89'7(->6
M^*_AI):A[W0PTL(Y>U/++_NGN/;K]:XZF'<=8E*1>\)?$I9C'8ZZRI(<*EWT
M!_W_`$^M>E`A@"""#R"*^82"K%6!!'!![5W7@CQY)I$D>G:G(TFGDX20\F'_
M`!7V[55'$?9F#CV/9:*;'(DL:R1L'1@"K*<@CU%.KM("BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHKC_B!XH.@Z3]FMGQ?70*H1U1>[?T'_P!:IE)15V!R_P`1?&1N99-$
MTZ7]PAQ<R*?OM_<'L._K7G**SNJ(I9F.``,DFD)).3UKU;X<^#A!%'KFH19F
M<9MHV'W!_?(]3VKSDI5IFFR+7@?P%'IB1ZGJL8>^/S1PMR(?<_[7\J[^BBO1
MA!05D9MW"BBBJ`****`"BBB@`HHHH`****`"BBB@#A/&W@*/6%?4=,18[\#+
MQ@8$_P#@WOWKQQT:-V1U*NIPRD8(-?3U>=?$7P<+R"36]/B_TF,9N(U'^L4?
MQ?4?J*Y*]&_O1*BS(^'?C)K*:/1=1ES;2'%O(Q_U;'^$^Q_0UZY7S!TKVOX>
M>*#K>EFRNGS?6H`)/61.S?7L?P]:6&JW]QA)=3M****["0HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@".>>.VMY)Y6"QQJ79CV`&37SQXBUF77]<N+^0G:[8C4_P`*#H/\]Z]0^*.L
MFQT&/3XFQ+>MAL'_`)9KR?S.!^=>-@%B`!DG@"N'%3N^5%Q1U7@/PU_PD&M!
MYTS8VN'EST8]E_'^0KW0````8`Z`5A^$=#70/#UO:E0)V'F3G')<]1^'3\*W
M:Z*-/DCYDMW"BBBMA!1110`4444`%%%%`!1110`4444`%%%%`!2$`C!Z4M%`
M'AOC_P`,C0=9\ZW3%E=Y>,#HC=U_J/8UAZ!K$VA:U;:A"3^[;YU_O(>H_*O<
M_%FB+K_AZXL\#S@/,A/HXZ?GR/QKY\961V1@0RG!![&O.K0]G.Z+3NCZ9MKB
M*[M8KF!P\4J!T8=P1D5+7`_"S63>:++IDK9DLVRF3UC;_`Y_,5WU=T)<\5(A
MJP44458!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`445'<3+;VTLS?=C0N<^@&:`/#OB)J9U'Q?<H&S%:@0*/<?>
M_4G\J9X`TD:KXLM@Z[H;;]^_''R]/UQ7.74[75W-<.26E<N<^I.:]3^$FGA+
M"_U!E^:200J?91D_S'Y5YM/]Y5NRWHCTBBBBO2("BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`*\)^(6DC2_%EPT:[8;H"=/3)^\/S!_.O=J\Z^+
M5@)-+LK]5^:&4QL?9AG^8K#$1O"_8<=SC/A_J9TWQ?:9;$=P3`_/][I^N*]X
MKYCAE:">.9#AXV#*1V(.:^EK2X6[LH+E>%EC60?0C-9X26CB.1-111762%%%
M59M3L+:4Q3WUM%(.J22JI'X$T7L!:HJDNL:8S!5U*S+$X`$ZY/ZU=I)I@%%%
M%,`HHJG)JVFPR-'+J%JCJ<,K3*"#[C-%[`7**@M[VUO-QMKF&?;][RG#8^N*
MGH`****`"BBB@`HHJK=:E8V7_'U>00GTDD"G]:+V`M45AOXQ\.QMAM8M<^SY
M_E0GC'P[(<+K%KGW?'\ZGGCW"QN455MM2L+P@6U[;S$]HY0Q_2K55>X!1110
M`4444`%%%5+G5-/LB1=7UO"1VDE`/Y4-V`MT5A-XR\.(V#K%KGV;-*GC'P[(
M<+K%KGW?'\ZGGCW"QN455M=2L;W_`(];RWF/I'(&/Z5:JD[@%%%%`!1110`4
M4A(4%F(`'))[52_MK2O^@G9_]_U_QI72`O45%!<0747F6\T<L9XW1L&'YBI:
M8!1110`4444`%%5+G5-/LI!'=7MO`Y&0LDH4D>N#4/\`PD&C?]!6R_[_`*_X
MTN9`:-%-21)45XW5T895E.013J8!1110`4453?5]-C=DDU&T5U."K3*"#^=)
MNP%RBJD.J:?<2K%#?6TDC=$296)_`&K=.]P"BFO(D4;22.J(HRS,<`#ZU3_M
MK2O^@G9?]_U_QI72`O451_MK2O\`H)V?_?\`7_&C^VM*_P"@G9_]_P!?\:.9
M`7J*H_VUI7_03L_^_P"O^-']M:5_T$[/_O\`K_C1S("]15'^VM*_Z"=G_P!_
MU_QH_MK2O^@G9?\`?]?\:.9`7J*:CI*BO&RNC#(93D$4ZF`445!=7MK91A[J
MYB@0G`:5PH)].:`)Z*SUU[2&8*NJ61).`!.O/ZUH4DT]@"BBBF`4444`%%%1
M3W5O:INN)XH5]9'"C]:`):*Q9?%WAZ%MKZO:9]I,_P`J8OC/PXQP-8M?Q;%3
MSQ[A8W:*H6^MZ5=X%OJ-I(3T"S+G\LU?III[`%%%%,`HHHH`**KW5_9V*[KJ
MZA@';S9`N?SK'E\;^&X<[M6@)'9,M_(5+DENP.@HKF1X_P##)./[37_OVW^%
M6HO&7AV<@)J]MD_WFV_SI>TCW'8W**@M[VUNUW6US#,/6-PW\JGJQ!1110`4
M444`%%%%`!6+XNN/LWA'59`<'[.R@^YX_K6U7,?$(E?`NI$'M&/_`"(M1-VB
MQK<\&KWCX>6WV;P58\<R;I#[Y8_TQ7@]?0WA%0OA'2@.GV9/Y5QX5>\RI&U1
M117>0%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5S/C^V%SX*U`
M8RT861?;##^F:Z:LGQ0GF>%-67&2;27`]]IJ9J\6@1\ZU]!^#)S<^#]+<MDB
M$*?P./Z5\^5[K\.'W^";/DG#2#G_`'C7%A7[[+EL=71117>0%?/OC3_D<M5_
MZ[FOH*OGSQI_R.6J_P#7<URXOX45'<PJ]-\!^/?+\K1]8E^3A;>X<]/16/IZ
M&N7\(>'HO$LNH63-Y=PMOYD$G8,&`P?8YK"O;*XTZ\EM+N)HIXFVLI[5RP<J
M=IHIZZ'TQ17EG@/Q[Y?E:/K$OR<+;W#GIZ*Q]/0UZG7HTZBFKHAJP5\VZT`N
MNZ@!T%S)_P"A&OI*OG#7T\OQ%J2YSBYD_P#0C7/B]D.)V_PB_P"0CJ?_`%Q3
M^9KUBO)_A#_R$M3_`.N*?S->L5IAOX:%+<****W$%<IXG\=Z;X>+6Z?Z5?`?
MZE#PO^\>WTZU#X_\5/X?TY+:T?%]<@[6_P">:]V^O8?_`%J\2=VD=G=BS,<E
MB<DFN6O7Y?=CN4E<Z/5O'6OZPS*;QK>)N!%;?(/SZG\Z--\#^(M8`E6S:.-N
M?-N6V9_/D_E7?^`_!5MIUC#JE_"LE]*H=%<9$*GI@?WO?M7>5,*#G[U1@W;8
M\CA^$>I,O[[4K5#Z(K-_A3+CX2ZL@S;WUG+[-N0_R->OT5K]6IBYF>!W7@;Q
M+8R`?V;+)SPT!#_RKT[P1H>M:7:>;J^HSN77Y+1GWB/ZD]_8<5UU%$*$8.Z!
MNX4445N(*YCQ5XUL?#*>21]HOF&5@4XVCU8]A^M7_$^MKX?T"YO\`R*-L2G^
M)ST_Q_"OGRYN9KRYDN;B1I)I6+.['))-<U>MR:+<I*YO:OXVU[67827CP0L>
M(;<E%^G')_&GZ9X$\1:LHE6T,,;<B2Y;9G\.OZ5U'PP\,P3QOKEW$)"KE+=6
M&0".K?7L/QKU*LZ=%U%S38-VV/)(OA'J)7][J=JA]%1F_P`*;-\(]34'R=1M
M'/HZLO\`0UZ[16WU:GV%S,\`U3P;K^AJ9I[1C$O/G0-N`]^.1^-2Z1X[U[2&
M4"[:YA'_`"RN#O&/8]1^=>]$9&#7C_Q*\*PZ7/'JMC&([>X?;+&HX1^N1Z`\
M_C]:QJ4737-!E)WW.[\+^--/\2H(E_T>]`RUNYZ^ZGN/UKI:^9+>XFM+B.XM
MY&CFC8,CJ<$&OH'PKK8\0>'[>^8`38V3`=G'7\^OXUI0K<^CW$U8VJ***Z23
M*\3_`/(K:K_UZR?^@FOG2OHOQ/\`\BMJO_7K)_Z":^=*X<7\2+B>R_"G_D5Y
M_P#KY;^0KNZX3X4_\BO/_P!?+?R%=W731_AHE[A1116H@HHHH`Y[Q7X3M?$]
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MY"RZE(OS-U$0_NK_`%-<*4J\KO8K9$?@GP3%X?@6\O%634G7D]1"#V'OZFNR
MHHKOC%15D09/B;3)M8\.WMA;NJS3)A2QXR"#@_E7E'_"K_$?]RU_[_?_`%J]
MMHJ*E&,W=C3L>)?\*O\`$?\`<M?^_P!_]:L[6_!6L:!8B\O8X?)+A"8Y-V">
MG%>_5QGQ0_Y$YO\`KXC_`*UC4P\(Q;0U)GB5=78_#O7]0L8;R&.`13('3?+@
MX/3BN4KZ+\,_\BOI7_7K'_Z"*PH4U-M,J3L>3_\`"K_$?]RU_P"_W_UJ4?"_
MQ&2!MM1[^=_]:O;**ZOJL">9E+2+`:7I%I8A@WD1*A8=R!R:NT45NE96)"O,
M_B__`,>^D_[\O\EKTRO,_B__`,>^D_[\O\EK+$?PV-;GE@ZBOIFT_P"/.#_K
MFO\`*OF4=17TU:?\>4'_`%S7^5883J5(FHHHKM("L7Q!XGTWPW;B2\E)E8?N
MX$Y=_P`.P]S3_$VNQ>'=$FOW`9Q\D2$_?<]!_7\*^?[^_N=3O9;R\E:6>0Y9
MC_(>@KGK5N31;E)7.IUGXDZWJ3,EJXL8#T$7WR/=O\,5DZ?X>\0>)'\Z"VN+
M@,>9YFPI_P"!-UKIOAWX-AU4'5]2CWVR-MAA8<2,.I/J!Z>M>N*BH@5%"J!@
M`#`%90I2J+FFP;ML>0V_PFU>0`W%]9Q9[+N<C]!4DOPCU%5_<ZG:NWHZLO\`
MC7KE%;?5J8N9GA-[\//$EB"PLA.H[P.&_3K^E=9X#\->(K687-]>W5E:*>+4
MMDR?53PH_6O2J*(X>,970^8****W)(YYXK:"2>9Q'%&I9V;H`.]>0>)?B5?W
M\TEOI#M:6@.!*/\`6./7/\/X<UZ%XXM+N^\(WT%D"TI4$JO5E!!('X5X"002
M",$5QXFI*+Y45%&CI^F:KXBOFCM8IKN<\NS-G'NS'I^-=A:?"74Y%!NK^U@)
M[(&<C^56?AKXFTG3;*;3KV1+::27S%F?A7&`,$]L8[^M>I12QS('BD5T/1E.
M12HT82C=Z@VSRX_""?!VZS&3[VY'_LU9EW\*]>@R;>6TN1V"N5;]1C]:]GHK
M9X:FQ<S/GFZ\-^(-)??+I]W$5/$D8)'YK7IWP_M?$GV;[5J]]/\`96&(K><;
MG/\`M$GD#VKN**(4%"5TP;N%%%%;B"BBB@`HHHH`*YCXA`MX%U(`=HS_`.1%
MKIZQ/%]N;GPCJD0&3]G9@/<<_P!*B:O%C6Y\]5]#>$6#>$=*(Z?9D_E7SS7O
M'P\N?M/@JQYYCW1GVPQ_IBN/"OWF5(ZBBBBN\@****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`K)\4/Y?A35FSC%I)@^^TUK5S/Q`N1;>"M0.<-(%
MC7WRPS^F:F;M%L$>"U[K\.$V>";/@C+2'G_>->%5]!^#(#;>#]+0K@F$,?Q.
M?ZUQ85>^RY;&[1117>0%?/GC3_D<M5_Z[FOH.OGSQI_R.6J_]=S7+B_A14=S
M<^%3X\52+G&ZV;CUY%=WXU\'1>)+/S[<*FHPC]VYX$@_NM_0]J\_^%[8\8J/
M6!Q_*O;**$5*E9@]&?,EQ;S6EQ);W$;131MM=&&"IKT3P'X\^S&/2-7E_<\+
M!<.?N?[+'T]#V^G3J?&G@J'Q';FYM@L6I1CY7/`D']UOZ&O$[JUGLKJ2VN8F
MBFC;:Z,,$&L)1E0E=#T9]-`YKYT\3*4\4:HK=1<R?S-=W\/_`!S_`*K1=5E_
MV;:=S^2,?Y'\*XSQG$8O&.JJ1C,Y;\^?ZU=>:G!20)69U?PA_P"0EJ?_`%Q3
M^9KUBO)_A#_R$M3_`.N*?S->L5OAOX:)EN%%%%;B/"?B+=/<^-+P,3MA"1(/
M0``_S)/XU@Z5`MUK%E;O]R6XC1OH6`KJOB?ICV?B@WFT^3>1A@W;<!@C]`?Q
MKD+*X-G?6]RHR89%D`^A!KRZFE1W[FBV/ID#`P.E%06EU#?6<-U;N'AE0.C#
MN#4]>H9A1110`4444`%%%%`'G/Q<F9=*TZ$$[7F9C^`_^O7DM>S_`!2TY[OP
MU'=1@DVDP9@/[IX)_/%>,5YV)7[PTCL>^>`D6/P5INT8W(S'Z[C725Q7PPU!
M+OPH+;=^\M9&1A['D']3^5=K7=2=X(A[A1115B"N7^(<*S>"KXM_RSV./J&%
M=17)?$>[2V\&72,1NG9(U![G.?Y`U%3X&-;GAE>L_"*8G3=1A.<+*K#\1_\`
M6KR:O8/A-:-%H-W<L,":?"GU"C_$FN##?Q$7+8]`HHHKTC,RO$__`"*VJ_\`
M7K)_Z":^=*^B_$__`"*VJ_\`7K)_Z":^=*X<7\2+B>R_"G_D5Y_^OEOY"N[K
MA/A3_P`BO/\`]?+?R%=W731_AHE[A1116H@HHHH`****`,#Q3X6M/$UAY<F(
M[J,'R9P.5/H?4>U>%:GIEWH]_)97L1CFC/([$=B#W%?2E<;\2=*M;SPO/>R1
MC[3:X:.0#D`L`1].:YJ]%27,MRDSS'3_`!CJVFZ#<:1!+B&7[KG.Z('J%/;-
M8MK;3WMU';6T32S2-M1%&234->N?"G2K5=)GU0QAKIY3$'(Y50!P/KFN2G%U
M)*+93T-?P;X+@\.6XN+@++J4B_/)U$8_NK_4]ZZVBBO2C%15D9A1115`%%%%
M`!7&?%#_`)$YO^OB/^M=G7&?%#_D3F_Z^(_ZUG5^!C6YXE7T7X9_Y%?2O^O6
M/_T$5\Z5]%^&?^17TK_KUC_]!%<N$^)E2-6BBBNX@****`"O,_B__P`>^D_[
M\O\`):],KS/XO_\`'OI/^_+_`"6L<1_#8UN>5CJ*^FK3_CR@_P"N:_RKYE'4
M5]-6G_'E!_US7^5883J5(FHHHKM(/*OB[=.;K3;3/[L(\N/4D@?T_6O-*]7^
M+6F22V=EJ<:DK"QBD]@W(/Y@C\17E%>9B$_:.YI'8^B/"D"6_A/2XT&!]F1C
M]2,G]2:V*YSP-J46I>$K%D8%X(Q#(O<,O'ZC!_&NCKT8-.*L9L****H`HHHH
M`****`"N2\2>`-+UYGN(O]#O3R98Q\KG_:7O]:ZVBIE%25F!X+K/@/7='+,;
M4W4`_P"6MO\`,,>XZC\JPX+R^T]_W%Q<6[`_P.5KZ6J">QM+K_CXM89?^ND8
M;^=<TL*KWBRN8\(M?'7B6TQLU69QZ2@/_P"A`UMV?Q7UF%@+NVM;A>^`48_B
M#C]*]$NO!7AR[!\S28%)[Q@H?TQ7-ZI\)]/F1GTR[EMY.R2_.A_J/UJ?95H[
M,+HLZ;\4]&NB%O8I[-C_`!$;U_,<_I796=]:ZA;K<6=Q'/$>CQL"*^=-5TN[
MT;49;&]CV31GG!R".Q![BM#PIXAN?#^LPS1.QMY&"SQ9X=?\1VHAB9)VF-Q[
M'T'12`A@".AYI:[2`HHHH`****`"HKB$7%M+"WW9$*'/N,5+10!\R7,#6UU-
M`X^:)RA^H.*]3^$FH!["_P!/9OFCD$RCV88/\A^=<E\1-,.G>+[E@N([H"=/
MQ^]^H-,\`:L-*\66Q=ML-S^X?GCYNGZXKS:?[NK9EO5'O%%%%>D0%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`5YS\6K_R]+L;!6YFE,K#V48'Z
MFO1J\)^(6K#5?%EP$;,-J/(3G@X^\?SS^588B5H6[CCN<S#$T\\<*#+R,%4#
MN2<5]+6ENMI906R\K%&L8^@&*\-^'^F'4O%]IE<QVY,[\?W>GZXKWBL\)'1R
M'(****ZR0KY\\:?\CEJO_7<U]!UY-XF^'VN:CXCO;VU2!X9Y-ZDR[3R.F#7-
MB8N459%1,CX9MCQI`/6*0?I7N%>8>#/`VMZ+XDAOKQ8$AC1@VV3<3D8Q7I]5
MAXN,+,4MPKE/&7@V#Q):^?`%BU&-?W<G0./[K?T/:NKHK645)68CYENK6>QN
MI+:YB:*>)MKHW!!IU[>W&H7'VBZD,DNU5+GJ0!@9]\"O;_%_@RV\2V_FQ[8=
M008CF/1A_=;V]^U>='X8^),G]U;G_ML*\^="<79:HM-&M\(?^0EJ?_7%/YFO
M6*X/X?>$]3\.W-[-J`B42HJH$?<>"37>5V4$U!)DO<****V$9'B/P_;>(])>
MRG^5Q\T4N,F-O7_$5X3K>@ZAH%Z;:^A*_P!R0<HX]0:^C:KWMA::E;-;7EO'
M/"W5'&1_^NL*M%5->HT['B?A/QS>>&R+>13<V!.3$3RGNI_I7JNE^,]!U9%,
M-_''(?\`EE.=C#\^OX5S>J_"C3[AFDTV[DM6/(CD&]/\1^M<O=?"_P`0P,?)
M%M<+ZI+C_P!"Q6,?;4]+70]&>U*RNH*L"#T(.:"0!DD`>]>$#P9XMM3B*PN%
MS_SSE']#4R^!?%UX`);:3'_3:<?XUI[>7\C"QZY?^)M$TU2;K4K=6'\"ON;\
MAS4NCZYI^NVIN-/N%E0'#+T93[CJ*\PM/A-JTI!NKVU@4]=N78?AP/UKL?#?
M@"T\.WJWJ7]S-.`00"$1A[@=?SJH3JMZQT%9'7T445N(CG@BNK>2"=`\4BE7
M5NA!ZBO#?%_@R[\.73S1(TNG.W[N4#.S_9;T/OWKW:FR1I-&T<J*Z,,,K#((
M]"*RJTE46HT['SYX7\27'AG51=1+YD+C;-%G&]?\1VKVO2?%FBZS&K6M]&)"
M.89"%<'TP>OX5SNM?"[2[YVFT^9[&0\[`-T?Y=1^=<A=_"_Q#;L?)%M<KZQR
MX_\`0L5SQ56EI:Z'HSVNBO"U\)^,K3Y(;6\0?],IP!^AI6\,>-9_DDM[]E/9
MY^/_`$*M/;R_E86/7]4\1:3H\;-?7T,;#_EF&RY^BCFO&?&7BR3Q/?KY:M%9
M09$4;'DGNQ]_Y5<MOAEXDN''F100`_Q23`_RR:ZC2/A/:0,LFJWC7)'/E1#8
MOXGJ?TJ)^UJZ6L@5D>?>'?#5]XDOU@M4*Q`CS9R/EC']3[5[YIFG6^DZ;!8V
MJ[885VCU/J3[D\U)9V5MI]LEM:0)#"GW408`J>MJ5%4UYB;N%%%%;",KQ/\`
M\BMJO_7K)_Z":^=*^DM8LY-0T6]LXBHDGA>-2W0$C'->/?\`"L?$G_/&W_[_
M``KCQ,)2:LBHLZOX7ZC96_AV>*>[@BD%P3MDD"G!`YYKN/[7TW_H(VG_`'^7
M_&O'/^%8^)/^>-O_`-_A1_PK'Q)_SQM_^_PHA4J1BER@TCV/^U]-_P"@C:?]
M_E_QH_M?3?\`H(VG_?Y?\:\<_P"%8^)/^>-O_P!_A1_PK'Q)_P`\;?\`[_"J
M]M4_E"R/:8+NVNMWV>XBFV_>\MPV/KBIJXGX?^$KSPXEY/J'EB>?:JJC;MJC
M/7ZD_I7;5T0;<;M6)844450!7-^/O^1)U+_<7_T(5TE8_BC3)]8\-WMA;%1-
M*@V;S@$@@X_2IFKQ:0(^=Z]I^%?_`"*3_P#7R_\`):X?_A6/B7_GC;_]_A7I
M7@?0[OP_X>^R7NP3-*TA"-D`'`Z_A7'AZ<HSNT7)Z'2T445W$!1110`4444`
M%<9\4/\`D3F_Z^(_ZUV=<YXVT6[U[PX]E9;#-YJN`[8!`]_QJ*J;@TAK<\"K
MZ+\,_P#(KZ5_UZQ_^@BO)?\`A6/B3_GC;_\`?X5[#H]I)8:+96DI4R0P)&VT
M\9``.*YL-"46[H<F7J***["0HHHH`*\S^+__`![Z3_OR_P`EKTRN+^(/AG4/
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M(VM:W.#_`,])P!^IK3V\_P"1A;S/9KW6=,TY2;R_MH<=GD`/Y=:J:1XJT;7+
MF6WL+P22Q\[6!4L/49ZBO,K3X5Z[.0;B6TMQWRY8_H/ZUTND_"RVL;B*YN-4
MN'FC8,OD`1X/UY--3JM_#H%D>@T445T$E#6-9L]"T][V^DV1KP`.68^@'<US
MEE\3O#UU@2R3VK'_`)ZQY'YKFK_B?P=:>*#&]Q=7,3Q*0FQ@5'OM-<+>?"34
MHV)L]0MIE["12A_J*YZDJJ?NK0:L>E6GB/1;X`V^J6CYZ#S0#^1YK25E8`JP
M(/0@UX7/\.?$T.<6*R#UCE4_UJNGA'Q7;G]WIMXA_P!AO\#4^WFMXCLCWVL;
M5?%6BZ-&QN[Z+>/^649WN?P']:\>/A/Q=<?*]A>L/21^/U-6[;X9^)+AAYD$
M$"G^*64?R&30Z\W\,0LC'\4:ZWB+79K_`,KRD("1IW"CIGWJ?PCX<N?$.L1(
MB$6L3!IY<<*/3ZFNYTGX36L++)JMZUP1R8H1M7\2>3^E=]8V%KIMJMM9P)!"
MO1$&!_\`7-1##RE+FF-R[%@```#H*6BBNT@****`"BBB@`HHHH`X/XI:,;W0
MH]1B7,MFWS8_N-P?R./UKQP$J00<$<@U]-W$$=U;RV\RAXI5*.I[@C!%?._B
M'1I=!UNXL)02$;,;'^)#T-<.*A9\R+BSV_PCKBZ_X>M[HL#.H\N<9Y#CJ?QZ
M_C6[7A7@/Q+_`,(_K02=\6-UA)<]%/9OP_D:]T!!`(.0>A%=%&ISQ\R6K"T4
M45L(****`"BBB@`HHHH`****`"BBB@`HHHH`***0D`$DX`H`Q?%FMIH'AZYO
M-P$Q'EPCU<]/RZ_A7SVS%V+,26)R2>YKK/'WB;^W]:\JW?-C:DI'Z.W=O\/8
M5B:!H\VNZU;:?"#^\;YV_NH.I_*O.K3]I.R+6B/3_A9HQL]&FU.5<27;83(Z
M(O\`B<_D*[^HK:WBM+6*V@0)%$@1%'8`8%2UW0CR142&[A1115@%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`5QWQ!\+G7=)%U:IF^M02@'61.Z_P!1_P#7KL:*F45)68'S`1@X->K_``Y\
M8BXBCT/4)<3(,6TC'[X_N'W':L[XB^#3:RR:WIT7[ASFYC4?</\`>'L>_I7G
M2,T;AT8JRG((."#7G)RHS--T?3U%<!X'\>QZHD>FZK*$OA\L<K<";V/^U_.N
M_KT834U=&;5@HHHJ@"BBB@`HHHH`****`"BBB@`HHHH`*\Y^(WC$6L+Z)I\O
M^D2#%S(I_P!6O]T>Y[^@^M6?''CR/28Y--TN17OR,22+R(?\6_E7CSNTCL[L
M6=CEF8Y)/K7)7KV]V)20VO;/AYX7.B:5]MNDQ?78!(/6-.R_7N?P]*Y?X=^#
M#>S1ZUJ,7^C1G-O&P_UC#^(^P_4UZY2PU*WOL)/H%%%%=A(4444`%%%>#7,E
MQJ'CJ6SFO[B**:^,;.)"-JE\<=JRJ5.2VFXTKGO-%<6/AWIL>2-:U=?4_:E'
M_LM<CXGM_P#A&ECFTGQ;<3S;]IMS<;F7WX./S%*5245=K\0L>Q45R?@'5=9U
M;16GU:,%0V()R-K2KW)'MZ]ZZRM(RYE=""BBBJ`***S?$,CQ>'-2>-BKK;.0
MRG!!VFDW97`TJ*\C^%5W<S>(+N.6XE=/LQ.UG)&=R_XUZY44Y\\>8;5@HHHK
M004444`%%>>^.?'L^CW;:7I847*J#+,PSY>>0`/7'K3=(\%ZAK5E%?Z_K=^S
MS*'$$4F-H/3)/\@*R]K>7+%7'8]#WK_>'YTM<@?AOHI7"SZ@I[,+@Y'Z5S?B
M'1]>\&0#4=)UNZFLU8!XYFW%,],@\$?@*)3E%7:"QZG17(^"/&/_``DT$L%S
M&L=]``6"?==?[P';GJ*ZZKC)25T(****H`HHKF=7\$V6L:C)>S:AJ43N`"D,
MX"C`QP"#BE)M;(#IJ*\F\;^%8O#>C17MEJ>HN[3B)EFFR,%6/8#TI/!'A:/Q
M)I,UY>ZGJ*,LQC589L#``/.0?6L?:RYN2VOJ.QZU17*:?X"L-.U"&\34=4E:
M%@ZI)<#:3[X`KJZUBV]T(****H`HHKGO',\MOX,U*6"1XY`B@,AP1EU!Y^AI
M2=DV!T-%>+>!M.;Q+>745]K%_$L*!E$5Q@MD^^>/\:[;_A`-/_Z#NL_^!8_^
M)K*%24U=(;1V=%<[H_A"UTB_6]BU+4KEE4@+/<;DYXS@`9KHJUBVUJ(****8
M!1110`4=*\N\3?$BZ>^?3=`50`_E_:2-Q=LX^4=,>]:MGX!O+V-9M?UV^FF8
M9:*&4A5]LG.?P`K'VO,[05QV[G=[E)P&'YTM<<_PWT9E_=W.HQ-V9;CG]16I
MH'AH:$7(U._N]PP%GERJ_0>M6G*^J`W:***L04444`%%%<I\1IY8/!MR\,KQ
ML7C!*-@XW#BIE+EBV!U=%>;_``HOI)K74HI[IG*NC*LCY(R#DC->C>8G]]?S
MI0GSQYAM6'45Y[\5;YX=(L8X+HH[SDE4?!(`]NV:TOAI/+/X01II7D83.`7;
M)`XXI*I>?(%M+G84445H(****`"BBB@`HHHH`****`"BBN,^)T\T'A0&&5XR
M;A`2C$9&#4SERQ;!'9T5P/PIN)I]"O?.FDDVW.!O8G'RCUKOJ(2YHJ0,****
MH`HHHH`**\,\77%[/X\O;6.\E3=.L:?O"`N0`/H.:W-"\::EX8U!M&\2I*\:
M'`E;YGC]\_Q+7.L0N:S17*>KT5%;W$-W;I<6\J2PR#<CH<@BO%A?W@^)P47<
M^/[1V8WG&W?C&/3'%:5*G);S$E<]NHHHK004444`%%9/B'7[7PYI3WMSEN=L
M<:]7;TKSS3-5\4>/=2FA@O\`^SK*(`R>2"-H/09ZD\'N.AK.=51?+NQV/6"P
M'4@4`@]"#7'1?#?3=N;K4-2N9>[M/C^E-?X<622![35M4MN>0L^?Z4<T^WXA
MH=I14%I;BTM([<2RR[!C?*^YF]R:GK004444`%%%%`!1110`4444`(RJZ,CJ
M&5A@@C((KQ[QOX"DTII-2TJ,O8D[I(AR8??W7^5>Q4A`(((R#6=2FIJS&G8^
M802""#@BO0_"GQ*ELE2RUO=-`.%N1RZ#_:_O#]?K6IXM^&J71DOM#58Y3\SV
MO16_W?0^W3Z5Y9<6\UI.\%Q$\4J'#(ZX(/TK@:G1D7HSZ4L[RVU"V2YM)TFA
M<?*Z'(-3U\X:1KNI:'<>=I]T\1/WEZJWU'0UZ/HOQ7MI0L6L6K0O_P`]H/F4
M_5>H_#-=4,3&7Q:$N)Z116?I^N:7JJAK&^@FS_"KC=^76M"NA-/8D****8!1
M110`45GZAK>F:4I-]?008_A9QN_+K7#ZU\5[:(-%H]JTS]/.F^51]%ZG\<5$
MJD8;L:5ST&[O+:PMGN+N>.&%!EG=L`5Y9XK^)<MV)++1"T,)RKW)X=O]W^Z/
M?K]*XO5]=U+7;CSM0NGE(^ZG15^@Z"J,$$US.D,$3RRN<*B#))^E<=3$.6D2
ME$82222<D]2:[KP1X#DU=X]1U.-H]/!RD9X,W^"^_>MKPE\-5@,=]KJJ\@^9
M+3J%_P!\]_I7I0`4````<`"JHX?[4P<NPD<:11K'&H1%`"JHP`/04ZBBNT@*
M***`"BBB@`KP"6SBU#Q])9SL5BFU`HY4X(!>O?ZXV]^&NB7M]-=O)=(\SEV"
MR#`).>.*PKTW.UAIV'-\-?#S##+=D>AG-<_XE\$:%X?TU]0@U&6UG3)A64B0
M2-_=`QG_``K<_P"%9Z3_`,_FH?\`?[_ZU*GPQ\/AMTINYCG^.;_`5+IW6D4.
MYB_#[QCJVI:J-*O1]IB,999@N#'@=\<8[?E7IM4-,T;3M&A,6GVD<"G[Q4<M
M]3U-7ZUIQE&-I.XF%%%%:""LOQ)_R+.I_P#7M)_Z":U*AN[6.]LYK68$Q3(4
M;!P<$8I-75@/(_A-_P`C)=?]>I_]"6O8JYWP_P"#-,\-W<MS9M.TLB;"9'!P
M,Y[#V%=%6=&#A"S&W<****U$%%%%`'B/Q'T6ZL/$L]\T;-:W9#I)C(!P`5/O
MQ^5>I>%=;L]:T.VDMY5,L<:I+%GYD8#!R/3WK7N+>"[@:"XB26)QAD=0P/X&
MN5N?AOH,LQFMEN;.3L;>4C'TSFL%3E"3E'J.]SKZXKXEZQ;V?AJ6Q\R,W-TR
MJ(\@D+G);';I^M2?\(`I&T^(=:,?]S[3Q_*I+/X<^'[:;SI89KN3J3<2%@3]
M!C-.7/)62L&ARGPFTRY_M&[U1HRMMY)A5B.&8L"<?3;^M>L4R**.")8HHUCC
M485$&`!["GU5.')'E!NX4445H(****`.%^*__(J0?]?B?^@/3?A/_P`BQ<?]
M?3?^@K74:]H-GXBT\65[Y@C#B0&-L$,,C^1-)H.@6?AVP:SLC(8V<R,9&R23
M@?TK'D?M>?H.^EC5HHHK804444`%<UX__P"1'U/_`'4_]#6NEJGJNF6^L:9/
M876[R9@`VTX/!!&/Q%3-7BT"/'/A_P"&].\17MY'J!D(AC5D1'VYR>M=[_PK
M'PW_`,\KG_O\:B3X6Z)&<I<7RGU$H']*?_PK/2?^?S4/^_W_`-:N>%)Q5G%,
MILZ71](M-#T];&R#B%26`=RQR:OURFG^`-,TZ_AO(KJ_:2%MRAIN"??`KJZZ
M(7MJK$A1115`%-D3S(V0DC<",CM3J*`/`&LY_"/B^W.I6Y9+><2=.)$!^\/6
MO<]-U6PU:V$]A=1SH1GY6Y'U'4?C3K_3;+5+<P7UK%<1^DBYQ]/3\*YB;X::
M$TADMFN[1_6&8\?GFN>%.5-OEU0V[G8TT.C,RJREE^\`>1]:Y`?#VU/$NL:O
M(G=6N>#^E:NB^$M)T"=Y[&*03.NUG>4L2/Y5JG)O5!H;E%%%6(****`"N0^)
MG_(E7'_76/\`]"%=?6?K6CVNNZ9)87>_RG(.4.""#D5$US1:0T>5_#SPMI?B
M&&^DU&.20Q,BH%<J!G.>E=M_PK3PS_SZ3?\`?]O\:U/#WAFP\-0S1V1E/G,&
M=I&R>.E;59TZ,5%*2U!L\@^(7A/2O#^GV=QIT<D;R2E'#2%@1C/>NL^%_P#R
M)R_]?$G]*W/$'ARR\26D=O>F4+&^]3&V"#C%2Z)HMKH&FK8V>\Q!BV7.22:(
MTN6IS+8+Z&E1116X@HHHH`****`"BBB@`HHHH`*XCXJ?\BDO_7RG\C7;UF:[
MH=IX@TXV5YY@CW!P8VP0145(N46D-;G(?"/_`)`5_P#]?/\`[**]"K(\/^';
M+PW9R6UD9"LC[V,C9).,?TK7HI1<8),'N%%%%6(****`/"/%+;?B-=-Z7:'_
M`-!KUSQ'X7T_Q+:>5=+LF0?NIU'S)_B/:J&H^`-'U+67U.9K@3.X=E23"DC\
M/:NJ`P,5A3I-.7-LQMGC5M=Z]\-]4%O=(9]-D;H#\CCU4_PM[?\`ZZS(KN"_
M^),%Y;,6AGU!)$)&#@L#R*]OO]/M=4LWM+V!9H''*L/U'H:YFR^&^AV&I0WL
M)N2\,@D1&DRH(Z=LUG*A*Z2>@[G7T445UDA1110!Q7Q+T6[U;08I;-&E>UD,
MC1J,EE(P2!WQ7.?#'Q!IVFI=:=>R);S32!TED.`W&-I/;']37K%86J^#M"UB
M1I;JP03-R98SL8_7'7\:PG3?/SQW&GI8W%974,I!4\@@Y!H9U12SL%4=23@"
MN-3X;Z?`<6NIZG;I_=CGP/Y5(/ASI,F/MEUJ%WC_`)[7!(J^:?;\0T.N!!`(
M.0:6J]C90:=916=JA2"(812Q.!]35BM$(****`"BBB@`HHHH`****`"BBB@`
MK'USPSI?B&'9?6X,@&$F3AU^A_H>*V**32:LP/%]=^&6K:<6ETXB_M^N%&)!
M_P`![_A^5<7-#+;RF*:-XY%ZJZD$?A7TY5'4-'T[58]E_90W`]77)'T/45RS
MPJ?PE*1\W*S(P9201T(-;-GXMU^P`$&K7(4=%=]X'X-FO2M0^%6C7!+6<]Q:
M,>BYWJ/SY_6N=NOA+JD9_P!%O[68?[89#_(UC[&K'8=T9T/Q.\21@!IK>3W>
M$?TQ4_\`PM3Q!_SSLO\`OT?\:JR_#7Q/&?ELXI?]R=/ZD5%_PKKQ5_T#!_X$
M1?\`Q5%Z_F&A9E^)WB24$++;Q^Z0C^N:Q[SQ;K]^"MQJUR5/54?8#^"XK4B^
M&OB>0C=9Q1?[\Z?T)K3M?A+JLA'VJ^M81_L;G/\`(4N6M+N&AY^S,[$L22>I
M)IT44D\BQQ1M([<!5&2?PKV#3_A3H]N0UY<7%T1_"#L7].?UKKM.T73=)CV6
M%E#`.Y1?F/U/4U<<+)_%H',>2:%\,]6U(K+?XL+<\G>,R$>R]OQKU'0O"^E>
M'HMME;CS2,/._+M^/8>PK9HKJIT8PV);N%%%%:B"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
=**`"BBB@`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
